Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $173.14 Average Price Target from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned an average recommendation of “Moderate Buy” from the fourteen research firms that are covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $173.43.

JAZZ has been the topic of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $205.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, September 10th. UBS Group cut their target price on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a report on Tuesday, July 2nd. JPMorgan Chase & Co. upped their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Robert W. Baird cut their price objective on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th.

Jazz Pharmaceuticals Trading Up 1.4 %

NASDAQ JAZZ opened at $109.55 on Friday. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals has a 1-year low of $99.06 and a 1-year high of $134.48. The firm’s fifty day simple moving average is $110.98 and its 200-day simple moving average is $109.57. The company has a market capitalization of $6.76 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 1.41 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals will post 16.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Kovack Advisors Inc. boosted its position in Jazz Pharmaceuticals by 88.8% in the first quarter. Kovack Advisors Inc. now owns 56,599 shares of the specialty pharmaceutical company’s stock valued at $6,816,000 after buying an additional 26,628 shares in the last quarter. John G Ullman & Associates Inc. acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $3,631,000. Swedbank AB bought a new stake in Jazz Pharmaceuticals during the 2nd quarter worth approximately $106,936,000. Vanguard Group Inc. increased its holdings in Jazz Pharmaceuticals by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after purchasing an additional 84,941 shares in the last quarter. Finally, LSV Asset Management raised its position in Jazz Pharmaceuticals by 1.6% in the 1st quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock valued at $286,703,000 after purchasing an additional 37,631 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.